title: Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
abstract: We investigated the brain magnetic susceptibility changes induced by natalizumab-associated progressive multifocal leukoencephalopathy. We retrospectively included 12 patients with natalizumab-progressive multifocal leukoencephalopathy, 5 with progressive multifocal leukoencephalopathy from other causes, and 55 patients with MS without progressive multifocal leukoencephalopathy for comparison. MR imaging examinations included T2* or SWI sequences in patients with progressive multifocal leukoencephalopathy (86 examinations) and SWI in all patients with MS without progressive multifocal leukoencephalopathy. Signal abnormalities on T2* and SWI were defined as low signal intensity within the cortex and/or U-fibers and the basal ganglia. We observed T2* or SWI signal abnormalities at the chronic stage in all patients with progressive multifocal leukoencephalopathy, whereas no area of low SWI signal intensity was detected in patients without progressive multifocal leukoencephalopathy. Among the 8 patients with asymptomatic natalizumab-progressive multifocal leukoencephalopathy, susceptibility changes were observed in 6 (75%). The basal ganglia adjacent to progressive multifocal leukoencephalopathy lesions systematically appeared hypointense by using T2* and/or SWI. Brain magnetic susceptibility changes may be explained by the increased iron deposition and constitute a useful tool for the diagnosis of progressive multifocal leukoencephalopathy.
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Departments of Neuroradiology (J.H., J.-P.P., X.L.) Jerome.hodel@gmail.com.
authors: J
authors: J
authors: Hodel
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Neurology (O.O., A.L., P.V.), Roger Salengro Hospital, Lille, France.
authors: O
authors: O
authors: Outteryck
authors: Department of Radiology (S.V.), Saint Philibert Hospital, Lille, France.
authors: S
authors: S
authors: Verclytte
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Department of Pathology (V.D.), Lille University Hospital, Lille, France.
authors: V
authors: V
authors: Deramecourt
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Neurology (O.O., A.L., P.V.), Roger Salengro Hospital, Lille, France.
authors: A
authors: A
authors: Lacour
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Departments of Neuroradiology (J.H., J.-P.P., X.L.).
authors: J-P
authors: JP
authors: Pruvo
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Neurology (O.O., A.L., P.V.), Roger Salengro Hospital, Lille, France.
authors: P
authors: P
authors: Vermersch
authors: From the University of Lille, CHU Lille (J.H., O.O., V.D., A.L., J.-P.P., P.V., X.L.), Lille, France Departments of Neuroradiology (J.H., J.-P.P., X.L.).
authors: X
authors: X
authors: Leclerc
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D001921:Brain / Q000473:pathology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D000069442:Natalizumab / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab